OncoMatch/Clinical Trials/NCT02859402
Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas
Is NCT02859402 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Busulfan and Fludarabine for t-cell non-hodgkin lymphoma.
Treatment: Busulfan · Fludarabine — Relapsed and refractory T-cell lymphomas have been reported to have dismal outcomes. The role of allogeneic stem cell transplantation have been demonstrated in these patients. This clinical trial is studying the efficacy and safety of busulfan plus fludarabine as conditioning therapy followed by allogeneic stem cell transplantation (Allo-SCT) in T- and NK/T-cell lymphoma patients who have relapsed or are refractory to previous chemotherapies including autologous transplantation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: chemotherapy
Relapsed after or refractory to one or more of previous chemotherapy including frontline autologous HSCT
Cannot have received: allogeneic stem cell transplant
Patients who have previously performed Allo-HSCT
Lab requirements
Kidney function
serum creatinine level < 2.0 mg/dL
Liver function
Transaminase (AST/ALT) < 3 X upper normal value (or < 5 x ULN in the presence of lymphoma involvement of the liver); Total bilirubin < 2 X upper normal value (or < 5 x ULN in the presence of NK/T involvement of the liver)
Cardiac function
Ejection fraction ≥ 50 % as measured by MUGA or 2D ECHO without clinically significant abnormality
Adequate renal function : serum creatinine level < 2.0 mg/dL; Adequate liver function : Transaminase (AST/ALT) < 3 X upper normal value (or < 5 x ULN in the presence of lymphoma involvement of the liver); Total bilirubin < 2 X upper normal value (or < 5 x ULN in the presence of NK/T involvement of the liver); Cardiac ejection fraction ≥ 50 % as measured by MUGA or 2D ECHO without clinically significant abnormality
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT02859402 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic stem cell transplant disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger and at least 19 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages